Concepedia

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Shambavi Richard, Alexander M. Lesokhin, Barry Paul, Jonathan L. Kaufman, Matthew J. Pianko, Noa Biran, Ravi Vij, Deon B. Doxie, Maryam I. Azeem, Mercedes Martillo,

Nature Cancer · 2024 · 20 citations · 15 references

DOIFull text

Open access

Concepts

References

15

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

Robert J. Johnston, Laëtitia Comps‐Agrar, Jason A. Hackney et al. · Cancer Cell · 2014 · 1.2K citations · Full text

, , +12

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

, , +17

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Soyoung Oh, Dai-Chen Wu, Jeanne Cheung et al. · Nature Cancer · 2020 · 459 citations

, , +17

T-cell engagement of dendritic cells rapidly rearranges MHC class II transport

Marianne Boes, Jan Černý, Ramiro Massol et al. · Nature · 2002 · 413 citations

, , +15

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Camille Guillerey, Heidi Harjunpää, Nadège Carrié et al. · Blood · 2018 · 297 citations · Full text

, , +16